SCHEMBL265403

SCHEMBL265403

CNS(=O)(=O)NC(=O)c1ccc(Cl)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.49
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MAPK1 P28482 3/20 0.48
F2 P00734 1/20 0.47
DAO P14920 1/20 0.47
KDM4E B2RXH2 4/20 0.47
MAPT P10636 2/20 0.47
KMT2A Q03164 6/20 0.47
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
MEN1 O00255 4/20 0.47
LMNA P02545 2/20 0.47
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
GSK3B P49841 1/20 0.43
TSHR P16473 2/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8244239 0.78 KDM4E (0.62) HPGDALDH1A1SMN1; SMN2MAPK1F2
SCHEMBL166992 0.71 F2 (0.63) HPGDALDH1A1SMN1; SMN2MAPK1F2
SCHEMBL27572930 0.70 F2 (0.52) HPGDALDH1A1SMN1; SMN2MAPK1F2
SCHEMBL3241403 0.70 AR (0.52) HPGDALDH1A1SMN1; SMN2MAPK1F2
SCHEMBL14627824 0.70 MAPK1 (0.64) HPGDALDH1A1SMN1; SMN2MAPK1F2
SCHEMBL13754450 0.70 SMN1; SMN2 (0.59) HPGDALDH1A1SMN1; SMN2MAPK1F2
SCHEMBL9283635 0.69 NPC1 (0.63) HPGDALDH1A1SMN1; SMN2DAOKDM4E
SCHEMBL6362178 0.68 MAPK1 (0.69) HPGDSMN1; SMN2MAPK1F2DAO
SCHEMBL27676813 0.68 MAPK1 (0.60) HPGDALDH1A1SMN1; SMN2MAPK1F2
SCHEMBL16673799 0.68 NPC1 (0.49) HPGDALDH1A1SMN1; SMN2MAPK1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629126-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC. (JP) 2014-01-14 US disclosed
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2012-05-31 US disclosed
US-8133882-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2012-03-13 US disclosed
US-8133882-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2012-03-13 US disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
EP-1995240-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY10, P2RY12, P2RY11 HPGD 1265/4885ALDH1A1 1934/4885SMN1; SMN2 4576/4885
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY12, P2RY11, P2RY10 HPGD 1450/4885ALDH1A1 2376/4885SMN1; SMN2 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.